SEC Company Response from BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) (BCRX) — Dec 8, 2017
BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)
Date: Dec. 8, 2017 · CIK: 0000882796 · Accession: 0001171843-17-007541
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221421
Letter
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(919) 859-1302
December 8, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Jeff Gabor
Re: BioCryst Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 8, 2017
As Amended by Amendment No. 1
Filed December 4, 2017
File No. 333-221421
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Standard Time, on December 12, 2017 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
BioCryst Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(919) 859-1302
December 8, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Jeff Gabor
Re: BioCryst Pharmaceuticals, Inc.
Registration Statement on
Form S-3
Filed November 8, 2017
As Amended by Amendment No. 1
Filed December 4, 2017
File No. 333-221421
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under
the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby
respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the
“Registration Statement”) be accelerated to 4:00 p.m., Eastern Standard Time, on December 12, 2017 or as soon thereafter
as practicable.
[Signature page follows]
Very truly yours,
BioCryst Pharmaceuticals, Inc.
/s/ Alane Barnes
Alane Barnes
Vice President, General Counsel and Corporate Secretary
cc: Robyn Zolman, Gibson, Dunn & Crutcher LLP